title: Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate.
abstract: Denosumab is a fully human monoclonal antibody against receptor activator of nuclear factor-kappaB ligand, an essential mediator of osteoclast activity and survival. In postmenopausal women with low bone mineral density (BMD), subcutaneous denosumab decreases bone resorption and increases BMD. This post hoc analysis reports on subjects treated for up to 24 months with denosumab 60mg 6 monthly (N=39), placebo (N=39), or open-label alendronate 70mg once weekly (N=38) in a phase 2 study. Hip scans were done by dual-energy X-ray absorptiometry at baseline, 12, and 24 months; these were analyzed with hip structural analysis software to evaluate BMD and cross-sectional geometry parameters at the narrowest segment of the femoral neck, the intertrochanter, and the proximal shaft. Geometric parameters and derived strength indices included bone cross-sectional area, section modulus, and buckling ratio. At 12 and 24 months denosumab and alendronate improved these parameters compared with placebo. Denosumab effects were greater than alendronate at the intertrochanteric and shaft sites. The magnitude and direction of the changes in structural geometry parameters observed in this study suggest that denosumab treatment may lead to improved bone mechanical properties. Ongoing phase 3 studies will determine whether denosumab reduces fracture risk.
authors.affiliation: Department of Radiology, Johns Hopkins School of Medicine, Baltimore, MD, USA. tjbeck@jhmi.edu
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Beck
authors.forename: E Michael
authors.initials: EM
authors.lastname: Lewiecki
authors.forename: Paul D
authors.initials: PD
authors.lastname: Miller
authors.forename: Dieter
authors.initials: D
authors.lastname: Felsenberg
authors.forename: Yu
authors.initials: Y
authors.lastname: Liu
authors.forename: Beiying
authors.initials: B
authors.lastname: Ding
authors.forename: Cesar
authors.initials: C
authors.lastname: Libanati
mesh_terms: D015502:Absorptiometry, Photon; D019386:Alendronate / Q000008:administration & dosage / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000069448:Denosumab; D005260:Female; D005269:Femur / Q000187:drug effects*; D006801:Humans; D016018:Least-Squares Analysis; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D053245:RANK Ligand / Q000008:administration & dosage / Q000494:pharmacology*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D053245:RANK Ligand; D000069448:Denosumab; D019386:Alendronate